These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9677534)

  • 61. Intra-lymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study.
    Pizza G; Viza D; De Vinci C; Vich i Pascuchi JM; Busutti L; Bergami T
    Lymphokine Res; 1988; 7(1):45-8. PubMed ID: 3283468
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interleukin-2 increases the antibody response in patients receiving autologous intralymphatic tumor cell vaccine immunotherapy.
    Williams TW; Yanagimoto JM; Mazumder A; Wiseman CL
    Mol Biother; 1992 Jun; 4(2):66-9. PubMed ID: 1515096
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
    Bovo G; Brivio F; Brenna A; Fumagalli L; Perego P; Brivio O; Uggeri F; Lavorato F; Bratina G
    Pathologica; 1995 Apr; 87(2):135-8. PubMed ID: 8532404
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P; Brivio F; Barni S; Tancini G; Cattaneo G; Archili C; Conti A; Maestroni GJ
    Anticancer Res; 1990; 10(6):1759-61. PubMed ID: 2285255
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
    Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute endocrine effects of interleukin-12 in cancer patients.
    Lissoni P; Rovelli F; Rivolta MR; Frigerio C; Mandalà M; Barni S; Ardizzoia A; Malugani F; Tancini G
    J Biol Regul Homeost Agents; 1997; 11(4):154-6. PubMed ID: 9582616
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
    Lissoni P; Mandalà M; Brivio F
    Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
    J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
    Lissoni P; Rovelli F; Mandalà M; Barni S
    Int J Biol Markers; 1998; 13(3):169-71. PubMed ID: 10079393
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Kinetics of cortisol, interleukin-2 and interleukin-3-like activity levels following surgical intervention.
    Fishman P; Nedivi R; Djaldetti M; Sredni B; Kayzer S; Chaimoff C
    Nat Immun; 1993; 12(1):35-40. PubMed ID: 8431662
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P; Pittalis S; Rovelli F; Vigorè L; Roselli MG; Brivio F
    J Biol Regul Homeost Agents; 1995; 9(2):63-6. PubMed ID: 9127635
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
    Lissoni P; Rovelli F; Giani L; Fumagalli L; Mandalà M
    Nat Immun; 1998; 16(5-6):178-84. PubMed ID: 11061586
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Preoperative subcutaneous immunotherapy with interleukin-2 in renal carcinoma with synchronous metastasis: randomized clinico-biological study. Preoperative use of Il-2 in renal carcinoma].
    Scardino E; Lissoni P; Andres M; Frea B; Favini P; Kocjancic E; Verweij F; Barani S; Tancini G; Rocco F
    Arch Ital Urol Androl; 1997 Feb; 69(1):49-54. PubMed ID: 9181906
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interleukin-12 in early or advanced cancer patients.
    Lissoni P; Rovelli F; Pittalis S; Casati M; Perego MS; Grassi MG; Brivio F; Fumagalli L
    Eur J Cancer; 1997 Sep; 33(10):1703-5. PubMed ID: 9389937
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
    Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
    Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
    [No Abstract]   [Full Text] [Related]  

  • 78. High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?
    Muhitch JB; Schwaab T
    Immunotherapy; 2014; 6(9):955-8. PubMed ID: 25341116
    [No Abstract]   [Full Text] [Related]  

  • 79. New clinical trials with interleukin-2: rationale for regional administration.
    Roth AD; Kirkwood JM
    Nat Immun Cell Growth Regul; 1989; 8(3):153-64. PubMed ID: 2674703
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
    Lissoni P; Fumagalli L; Giani L; Rovelli F; Confalonieri G; Pescia S
    Int J Biol Markers; 1998; 13(2):98-101. PubMed ID: 9803358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.